 gpASITTM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this study is to demonstrate the clinical efficacy and safety of a subcutaneous immunotherapy with gpASITTM in patients with grass pollen-induced allergic rhinoconjunctivitis compared to placebo. 